Aptiom eslicarbazepine acetate regulatory update

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary said Health Canada approved Aptiom eslicarbazepine acetate as a once-daily adjunctive therapy to treat partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. The company plans to launch the voltage-gated sodium and T-type calcium channel blocker in November. ...